Cardiovascular and renal findings in incretin research
Why outcome trials — not surrogate markers — reshaped how incretin science is understood.
The most consequential incretin findings are not about glucose or weight but about hard outcomes. Large trials reported lower rates of major cardiovascular events among participants with type 2 diabetes and established atherosclerotic disease, and in 2025 semaglutide received regulatory approval for reducing cardiovascular and kidney disease risk on that basis. Reviews of the class now describe metabolic, cardiovascular, and renal benefit together.
The methodological point is as important as the clinical one. For decades, glucose-lowering was assumed to deliver cardiovascular benefit — a surrogate standing in for the outcome that matters. That assumption did not always survive testing. Outcome trials measure events directly, which is why they carry the weight they do; see Clinical trial phases.
Whether benefit follows from weight change, from glycaemia, or from direct receptor effects on vasculature and kidney is still being resolved. Reported as published research, not as advice about treatment.
Related articles
- MetabolicGLP-1 receptor agonistsHow GLP-1 works, and why molecules mimicking it became central to metabolic research.
- MetabolicDual GIP/GLP-1 receptor agonistsEngineering one molecule to engage two incretin receptors — and what head-to-head data showed.
- MethodsBiomarkers and surrogate endpointsMeasuring something easy in place of something that matters — useful, and quietly dangerous.
- MethodsClinical trial phasesWhat each stage of clinical testing is actually designed to answer.
- MetabolicMetabolic syndromeThe cluster of findings — central adiposity, dysglycaemia, dyslipidaemia, raised blood pressure — that tend to travel together.
- MetabolicThe incretin effectThe observation that started incretin science: glucose taken by mouth triggers far more insulin than the same glucose given intravenously.